Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G
Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany.
Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9.
Meropenem is a broad-spectrum antibiotic used for severe infections. In patients with chronic end-stage renal failure, meropenem clearance is reduced and doses must be adjusted according to the creatinine clearance. The aim of this study was to assess pharmacokinetic data of meropenem in patients with acute renal failure and to determine the amount of drug removed by continuous venovenous hemofiltration, an often-used renal replacement therapy in patients with acute renal failure.
Nine critically ill anuric patients with acute renal failure undergoing continuous venovenous hemofiltration received 500 mg meropenem 2 or 3 times daily. Plasma and hemofiltrate concentrations were determined during 1 dosing interval at steady state. Pharmacokinetic parameters were calculated for a 2-compartment open model and dose requirements were calculated.
The total meropenem clearance was 52.0 +/- 8.4 mL/min, with a hemofiltration clearance of 22.0 +/- 4.7 mL/min and a nonrenal-nonhemofiltration clearance of 29.9 +/- 5.4 mL/min; 235.9 +/- 88.6 mg, or 47.2% +/- 17.7%, of the dose were removed through continuous venovenous hemofiltration. The terminal elimination half-life was 8.7 +/- 3.5 hours and the volume of distribution at steady state was 12.4 +/- 1.8 L. Peak and trough concentrations for a dosing interval of 12 hours were 38.9 +/- 9.7 mg/L and 7.3 +/- 1.3 mg/L, respectively. The corresponding concentrations for a dosing interval of 8 hours were 44.7 +/- 10.4 mg/L and 11.9 +/- 0.7 mg/L, respectively.
Pharmacokinetic data of anuric patients with acute renal failure were similar to those of patients with end-stage renal failure. Because hemofiltration contributes significantly to meropenem elimination, the recommended dose for critically ill anuric patients receiving continuous venovenous hemofiltration should be increased by 100% to avoid potential underdosing.
美罗培南是一种用于严重感染的广谱抗生素。在慢性终末期肾衰竭患者中,美罗培南清除率降低,剂量必须根据肌酐清除率进行调整。本研究的目的是评估急性肾衰竭患者中美罗培南的药代动力学数据,并确定通过持续静静脉血液滤过(急性肾衰竭患者常用的肾脏替代治疗方法)清除的药物量。
9例接受持续静静脉血液滤过的急性肾衰竭无尿重症患者,每天2或3次接受500mg美罗培南治疗。在稳态下的1个给药间隔期间测定血浆和血液滤过液浓度。计算二室开放模型的药代动力学参数并计算剂量需求。
美罗培南总清除率为52.0±8.4mL/min,血液滤过清除率为22.0±4.7mL/min,非肾非血液滤过清除率为29.9±5.4mL/min;235.9±88.6mg,或剂量的47.2%±17.7%,通过持续静静脉血液滤过被清除。终末消除半衰期为8.7±3.5小时,稳态分布容积为12.4±1.8L。12小时给药间隔的峰浓度和谷浓度分别为38.9±9.7mg/L和7.3±1.3mg/L。8小时给药间隔的相应浓度分别为44.7±10.4mg/L和11.9±0.7mg/L。
急性肾衰竭无尿患者的药代动力学数据与终末期肾衰竭患者相似。由于血液滤过对美罗培南清除有显著贡献,接受持续静静脉血液滤过的无尿重症患者的推荐剂量应增加100%,以避免潜在的剂量不足。